Disease-specific animal models supporting preclinical pharmacology

Disease-specific animal models: Strengthening confidence in preclinical pharmacology

01

Understanding the role of experimental animal models in translational drug discovery

Experimental animal models remain fundamental to translational drug discovery, providing critical insights into disease etiology, pathophysiology, and progression under controlled biological conditions. These models enable systematic evaluation of pharmacokinetics, pharmacodynamics, safety, and therapeutic efficacy, thereby supporting informed decision making prior to clinical advancement.

Researcher working in a pharmacology laboratory with disease-specific animal models
Disease-relevant animal models help bridge preclinical findings and clinical outcomes.

Explore our pharmacology and in vivo imaging solutions supporting translational research.

02

Disease phenotype modeling beyond healthy animals

To investigate defined disease phenotypes, mutant and disease-specific animal models have been developed to reproduce species comparable physiological and pathological states. Examples include diet induced and genetic obesity models, immunodeficient strains, and accelerated aging models.

Such systems have contributed significantly to elucidating disease mechanisms and assessing therapeutic modulation in biologically relevant contexts that extend beyond conventional healthy animal models.

03

Addressing translational limitations of conventional animal models

However, inherent interspecies differences limit the ability of traditional animal models to fully recapitulate the complexity of human disease. This translational limitation has led to the development of advanced genetically engineered platforms, particularly rodents engrafted with human cells, tissues, or immune components commonly referred to as humanized animal models.

These systems offer improved representation of human specific biological processes and are increasingly integrated into contemporary preclinical development paradigms.

04

Humanized animal models and improved clinical relevance

Humanized models enable functional characterization of candidate therapeutics within human relevant biological environments, thereby enhancing predictive validity and clinical translatability. Importantly, these models also support the study of interindividual variability and patient specific responses, aligning with the growing emphasis on precision and personalized medicine approaches.

05

Strategic importance of disease-specific and humanized models

As therapeutic strategies continue to evolve toward mechanistic and targeted interventions, the strategic application of disease-specific and humanized animal models remains central to the development of safer, more effective, and more translatable therapies.

06

Disease-specific models in adgyl’s scientific strategy

Disease-specific animal models are central to Adgyl’s translational strategy, enabling high-precision, mechanistic preclinical data and reducing uncertainty during clinical transition in target-driven drug discovery. Read more about Adgyl.

07

Scientific rationale for integrating disease-specific animal models

Conventional models frequently fail to capture the molecular and cellular complexity of human disease, often resulting in limited predictive power. To address this challenge, Adgyl integrates disease-specific animal models into study design to:

  • Improve mechanistic insight and translational predictability
  • Support data-driven go/no-go decisions during early development

These models underpin our approach to generating reproducible, interpretable, and clinically relevant preclinical evidence.

08

Translational model platforms supporting drug development decisions

Adgyl’s disease-specific model platforms are designed to support critical stages of drug development through integrated pharmacological and biological assessment. Leveraging cross-disciplinary expertise in pharmacology, pathology, molecular biology, and model development, we support global research programs in areas including:

Our platforms align preclinical outcomes with downstream clinical objectives.

09

Advanced modeling capabilities for predictive pharmacology

Adgyl continuously expands its model portfolio through investment in advanced experimental platforms, including CRISPR-engineered genetic models, humanized immune system models, orthotopic and syngeneic tumor models, inducible disease systems, and customized transgenic development aligned with target biology. These approaches enable mechanistic interrogation of therapeutic responses under disease-relevant conditions and support generation of data that is both scientifically robust and regulatorily aligned.

Learn more about our pharmacology solutions and safety pharmacology capabilities.

12

Reference

  1. Singh, V. K., & Seed, T. M. (2021). How necessary are animal models for modern drug discovery? Expert opinion on drug discovery, 16(12), 1391-1397.
Let’s collaborate

Advance your drug development with Adgyl Life Sciences

From target validation to PK/PD and biomarker studies, our scientific experts are ready to discuss how we can support your next project.

Scientific expertise
Regulatory-aligned solutions
End-to-end support